62 completed, 15 active not recruiting, 15 unknown, 13 recruiting. 49 Phase 2, 41 Phase 1, 22 Phase 3, 4 Phase 4, 3 Not applicable.
Follow Crizotinib: new trials by email Literature Review of Crizotinib trials Research Report on Crizotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer JYP0322 Tablets, Crizotinib Capsules - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 3 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 216 | 2026-10-30 | 2026-09-22 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line - Signet Ring Cell Carcinoma of the Lung | Recruiting | First People's Hospital of Hangzhou | 39 | 2025-09-01 | 2025-10-03 | |
| A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Taletrectinib, Crizotinib - Non Small Cell Lung Cancer | Phase 3 | Recruiting | Nuvation Bio Inc. | 194 | 2024-11-27 | 2026-04-13 |
| Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. Sunvozertinib, Crizotinib, Pralsetinib - Lung Cancer Stage III, Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 120 | 2024-11-01 | 2026-04-21 |
| A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC SY-3505 Capsules, Crizotinib Capsules - Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | Shouyao Holdings (Beijing) Co. LTD | 255 | 2024-05-01 | 2024-02-12 |
| A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) Repotrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 190 | 2023-12-21 | 2026-09-22 |
| TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) TGRX-326, Crizotinib - Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shenzhen TargetRx Co., Ltd. | 321 | 2023-12-14 | 2025-05-18 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib XZP-3621, Crizotinib - Non-small Cell Lung Cancer | Phase 3 | Unknown | Xuanzhu Biopharmaceutical Co., Ltd. | 238 | 2022-02-07 | 2022-01-24 |
| Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC Drug: Foritinib Succinate, Drug: Crizotinib - Non-Small Cell Lung Cancer, ALK-positive | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 275 | 2021-12-31 | 2024-08-26 |
| Crizotinib Continuation Clinical Study crizotinib - NSCLC, ALCL | Phase 4 | Active not recruiting | Pfizer | 27 | 2021-12-27 | 2026-03-30 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma Crizotinib - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 90 | 2021-11-13 | 2024-09-20 |
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases Entrectinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Hoffmann-La Roche | 217 | 2021-09-30 | 2026-08-13 |
| Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) Crizotinib - Healthy Participants | Phase 1 | Completed | Pfizer | 25 | 2021-04-16 | 2022-01-20 |
| Antineoplastic Drugs in Elderly Patients Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs) - Cancer | Recruiting | Shandong University | 500 | 2021-01-01 | 2022-07-20 | |
| Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. crizotinib, alectinib, brigatinib - ALK-positive NSCLC | Completed | Pfizer | 549 | 2020-12-14 | 2023-04-06 | |
| Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial Axitinib, Crizotinib, Palbociclib Isethionate - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 111 | 2020-12-01 | 2026-09-18 |
Showing 20 of 125. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (50) · Lung Neoplasms (12) · Lymphoma, Large-Cell, Anaplastic (8) · Neoplasms (8) · Neoplasm Metastasis (7) · Lymphoma (6) · Multiple Myeloma (6) · Adenocarcinoma (4) · Colorectal Neoplasms (4) · Granuloma, Plasma Cell (4) · Uveal Melanoma (4) · Carcinoma, Renal Cell (3) · Hematologic Neoplasms (3) · Melanoma (3) · Neuroblastoma (3)
Pfizer (40) · National Cancer Institute (NCI) (10) · Hunan Province Tumor Hospital (5) · Hoffmann-La Roche (4) · M.D. Anderson Cancer Center (4) · IDEAYA Biosciences (3) · Bristol-Myers Squibb (2) · Children's Oncology Group (2) · Oslo University Hospital (2) · Samsung Medical Center (2) · Ariad Pharmaceuticals (1) · Astex Pharmaceuticals, Inc. (1) · Canadian Cancer Trials Group (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
United States (61) · China (35) · South Korea (18) · Canada (17) · Italy (17) · Spain (16) · France (15) · Japan (14) · Germany (13) · United Kingdom (13) · Australia (12) · Taiwan (12) · Belgium (10) · Netherlands (10) · Russia (10)
Yongchang Zhang, MD (5) · David S Hong (2) · Aaron S Mansfield (1) · Alice T Shaw (1) · Anna Vinitsky, MD (1) · Anne Hansen Ree, Prof. MD PhD (1) · Caicun Zhou (1) · Carlo Gambacorti Passerini, MD (1) · Christopher Sweeney, MD (1) · Daniel J Renouf (1) · David Camidge (1)
PMID 41920422, PMID 28373069, PMID 28501139, PMID 30822515, PMID 25436806, PMID 25624436, PMID 26381275, PMID 27130468, PMID 29074098, PMID 20979469, PMID 20979472, PMID 21422405, PMID 21623265, PMID 21767331, PMID 21933749, PMID 22088989, PMID 22316363, PMID 22954507, PMID 23169500, PMID 23598171, PMID 23724913, PMID 23724914, PMID 24128715, PMID 25264305, PMID 25559471, PMID 25876560, PMID 26062823, PMID 26586415, PMID 26698910, PMID 28032129, PMID 28586279, PMID 28950372, PMID 29209525, PMID 29216400, PMID 29468455, PMID 29567632, PMID 29596029, PMID 29656744, PMID 29669701, PMID 29966800, PMID 30215676, PMID 30280657, PMID 30413378, PMID 30652510, PMID 30980071, PMID 30981696, PMID 31008509, PMID 31171735, PMID 31346927, PMID 31584608
U10CA180820 (6), U24CA196172 (4), 2009 (3), 2015 (3), 2023 (2), U10CA180830 (2), U10CA180868 (2), U10CA180888 (2), UM1CA097452 (2), 2005 (1), 2014 (1), 2017 (1), 2019 (1), P30CA016672 (1), U10CA021115 (1)